Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 3/20 | 1.00 |
| ▸ | CELA1 | Q9UNI1 | 2/20 | 1.00 |
| ▸ | PREP | P48147 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | RECQL | P46063 | 3/20 | 0.45 |
| ▸ | BLM | P54132 | 3/20 | 0.45 |
| ▸ | APEX1 | P27695 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 2/20 | 0.45 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.45 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.45 |
| ▸ | EED | O75530 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | G6PD | P11413 | 1/20 | 0.45 |
| ▸ | CBR1 | P16152 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.43 |
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29740511 | 0.83 | PREP (0.70) | KDRCELA1PREPMEN1KMT2A | |
| SCHEMBL29592207 | 0.82 | PREP (0.68) | KDRCELA1PREPMEN1KMT2A | |
| SCHEMBL29435454 | 0.79 | KDR (0.65) | KDRCELA1PREPMEN1KMT2A | |
| SCHEMBL31438443 | 0.73 | KDR (0.56) | KDRCELA1PREPMEN1KMT2A | |
| SCHEMBL29448441 | 0.71 | PREP (0.54) | KDRCELA1PREPMEN1KMT2A | |
| SCHEMBL2417272 | 0.71 | KDM4E (0.59) | KDRCELA1PREPTHRBKDM4E | |
| Ellagic Acid Tetraacetate SCHEMBL3801268 | 0.66 | CA12 (0.54) | KDRCELA1PREPMEN1KMT2A | |
| 6'-Desmethylcandidusin B SCHEMBL31410089 | 0.64 | ACHE (0.56) | KDRCELA1PREPMEN1KMT2A | |
| SCHEMBL437459 | 0.64 | ALDH1A1 (0.60) | KDRCELA1PREPMEN1KMT2A | |
| SCHEMBL3887841 | 0.63 | KDR (0.54) | KDRCELA1PREPMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705765-A2 | BUCCAL CELL DIAGNOSIS OF RISK IN FAMILIAL ARRHYTHMIA SYNDROMES | Beth Israel Deaconess Medical Center, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250041408-A1 | SMALL MOLECULE IMMUNOPOTENTIATOR CONJUGATES OF NFKB ACTIVATORS AS ADJUVANTS WITH ENHANCED EFFICACY AND REDUCED TOXICITY | THE UNIVERSITY OF CHICAGO | 2025-02-06 | — | — | US | disclosed |
| US-20240415801-A1 | Methods and Compositions for Treating Fibroids | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 2024-12-19 | — | — | US | disclosed |
| WO-2024226767-A2 | BUCCAL CELL DIAGNOSIS OF RISK IN FAMILIAL ARRHYTHMIA SYNDROMES | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| US-20220387561-A1 | TREATMENT OF SEVERE ACUTE RESPIRATORY SYNDROME-RELATED CORONAVIRUS INFECTION WITH KLOTHO | COSTA RICAN SOCIAL SECURITY FUND / CAJA COSTARRICENSE DE SEGURO SOCIAL CCSS (CR) | 2022-12-08 | — | — | US | disclosed |
| WO-2022008971-A2 | TREATMENT OF SEVERE ACUTE RESPIRATORY SYNDROME-RELATED CORONAVIRUS INFECTION WITH KLOTHO | Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) (CR) | 2022-01-13 | — | — | WO | disclosed |
| US-20220008519-A1 | TREATMENT OF SEVERE ACUTE RESPIRATORY SYNDROME-RELATED CORONAVIRUS INFECTION WITH KLOTHO | Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) (CR) | 2022-01-13 | — | — | US | disclosed |
| US-20210346495-A1 | METHODS AND COMPOSITIONS COMPRISING AN NFKB INHIBITOR AND AN ADJUVANT | THE UNIVERSITY OF CHICAGO (US) | 2021-11-11 | — | — | US | disclosed |
| US-20210161868-A1 | ANTI-INFLAMMATORY THERAPY IN ARRHYTHMOGENIC CARDIOMYOPATHY (ACM) | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2021-06-03 | — | — | US | disclosed |
| US-20210093612-A1 | SYSTEMS AND METHODS TO TREAT PAIN LOCALLY | WARSAW ORTHOPEDIC INC (US) | 2021-04-01 | — | — | US | disclosed |
| EP-2043625-B1 | NFKAPPAB INHIBITORS TO TREAT PAIN LOCALLY | MEDTRONIC INC (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20110268722-A1 | COMBINATION THERAPIES WITH MITOCHONDRIAL-TARGETED ANTI-TUMOR AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-11-03 | — | — | US | disclosed |
| WO-2011133879-A2 | COMBINATION THERAPIES WITH MITOCHONDRIAL-TARGETED ANTI-TUMOR AGENTS | UNIVERSITY OF MASSACHUSETTS (US) | 2011-10-27 | — | — | WO | disclosed |
| EP-2363122-A1 | Clonidine to treat pain locally | Medtronic, Inc. (US) | 2011-09-07 | — | — | EP | disclosed |
| US-20100159015-A1 | Systems and Methods to Treat Pain Locally | WARSAW ORTHOPEDIC, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100151000-A1 | COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES | THE UNIVERSITY OF QUEENSLAND (AU) | 2010-06-17 | — | — | US | disclosed |
| CN-101646418-A | Compositions and methods for modulating immune responses | UNIV QUEENSLAND AU | 2010-02-10 | — | — | CN | disclosed |
| EP-2043625-A1 | NFKAPPAB INHIBITORS TO TREAT PAIN LOCALLY | Medtronic, Inc. (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008014066-A1 | NFKAPPAB INHIBITORS TO TREAT PAIN LOCALLY | MEDTRONIC, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| US-20060253100-A1 | Systems and Methods to Treat Pain Locally | MEDTRONIC, INC. (US) | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110268722-A1 | COMBINATION THERAPIES WITH MITOCHONDRIAL-TARGETED ANTI-TUMOR AGENTS | TFAM, AIFM1, MAVS | KDR 405/4885CELA1 4503/4885PREP 3403/4885 |
| US-20210346495-A1 | METHODS AND COMPOSITIONS COMPRISING AN NFKB INHIBITOR AND AN ADJUVANT | NFKBIA, IKBKG, NFKB2 | KDR 4240/4885CELA1 2332/4885PREP 2785/4885 |
| US-20250041408-A1 | SMALL MOLECULE IMMUNOPOTENTIATOR CONJUGATES OF NFKB ACTIVATORS AS ADJUVANTS WITH ENHANCED EFFICACY AND REDUCED TOXICITY | NFKBIA, NFRKB, NFKB2 | KDR 952/4885CELA1 3831/4885PREP 3811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.